CeMM Adjunct Principal Investigator

Thomas Reiberger
Rare Liver Diseases & Hepatic Microcirculation

Prof. Dr. Thomas Reiberger
Medical University of Vienna
Department of Internal Medicine III
Div. of Gastroenterology & Hepatology
Vienna Hepatic Experimental Hemodynamic Lab
Waehringer Guertel 18-20, 1090 Vienna


Thomas Reiberger conducted seminal studies for optimizing the role of non-selective betablocker therapy in patients with cirrhosis and portal Hypertension (Reiberger, Gut, 2013; Mandorfer, Gastroenterology 2015; Reiberger, Journal of Hepatology, 2017). His HEPEX research team is focused on exploring novel treatment options for liver fibrosis and portal hypertension, such as anti-angiogenic drugs (Reiberger, Journal of Hepatology 2009), FXR agonsits (Schwabl, Journal of Hepatology, 2017) and soluble guanylate cyclase stimulators (Schwabl, Scientific Reports 2018). Thomas Reiberger is also the clinical director of the cirrhosis outpatient clinic and the Vienna Hepatic Hemodynamic Laboratory at the Division of Gastroenterology & Hepatology.

Main Research Interests:
Liver fibrogensis and inflammation
Portal hypertension
Rare liver diseases causing non-cirrhotic portal hypertension


Thomas Reiberger, born 1982, joined the LBI-RUD and CeMM in 2018 as an Adjunct PI. After obtaining his MD at the Medical University of Vienna, he did a first postdoc at the Department of Pathophysiology at the Medical University of Vienna, where he performed his first studies in the field of Liver Cell Biology. During his residency for Internal Medicine at the Divison of Gastroenterology and Hepatology at the Medical University of Vienna, Thomas Reiberger followed the career of a physician scientist and focused his translational studies on portal hypertension and fibrosis in patients with viral hepatitis. Next to the clinic he established the Vienna Hepatic Experimental (HEPEX) Laboratory at the Medical University of Vienna. In 2011 he received his Venia docendi and 2012 he obtained his board certification for Internal Medicine. After another postdoctoral fellowship in the United States from 2012 to 2015, Thomas Reiberger was appointed as Associate Professor of Gastroenterology and Hepatology at the Medical University of Vienna. 

Selected Papers

Reiberger T, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol. 2009 Nov;51(5):865-73.

Reiberger T, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013 Nov;62(11):1634-41.

Reiberger T, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013 May;58(5):911-21.